Portal de investigación
Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Gustavo, F
- Todo, R
- Meier, L
- Martínez, MT
- López, ME
- Paris, L
- O'Connor, M
- Merino, LD
- Martinez-Jañez, N
- Antón, FM
- Fernández, I
- Keane, M
- Garcia-Palomo, A
- Starus, A
- Portela, M
- Herranz, J
- Caballero, R
- Jones, F
- Albanell, J
- Jesus Alarcon Co
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0732-183X, 1527-7755
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 9,378 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF CLINICAL ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Gustavo,F,Todo,R,Meier,L,Martínez,MT,López,ME,Paris,L,O'Connor,M et al. Plasma mutational burden in <i>PIK3CA</i> and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial. Special Clinical Science Symposia. 2024. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2024.